|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
 Zaslal: 26.9.2021 15:14 What Does origins of Judaism Mean? |
BOOK: "Biblical Moses and the last king of Mari Zimri-Lim are the same person". USA, “THE EAST: Ancient & Modern”. 2021. ISBN: 9781953594990 (URL: https://zen.yandex.ru/media/id/5f9757a86 c94b928e6cde43e/biblical-moses-and-the-l ast-king-of-mari-zimrilim-are-the-same-p erson-613e6db5c5ad3f1f798dae3c) link: https://zen.me/249Pnox2]
ANNOTATION: In the book, referring to the 3 independent sources written in the XVIII century BC, the author establishes that Moses, Joshua and other characters of the Torah actually existed in real history, and the Exodus of the Jews did actually happen. Referring to those sources, author recreates the true picture of the events, as well as restores the further fate of the heroes of the Pentateuch. According to this source, author states that Moses is the last king of Mari = Zimri-Lim; Jethro = Sumu-Epuh (king of Yamhad); "Pharaoh-oppressor" = Samsi-Adad I (king of Assyria); "Pharaoh of Exodus" = Hammurabi; Chedorlaomer = Joshua; country of Midian = Yamhad; country of Kush = Moab = Qatna = Nabatea, Harran = Hauran = region of Basan, Reed Sea = The Dead Sea. Finally, the Exodus had occurred in 1759 BC in Mari, 2 years after its occupation by Hammurabi. According to the author, Moses was violently killed in about 1745 BC on the territory of modern Jordan. Abraham was his younger contemporary. The authorship of "Genesis" belongs to Joseph.
KEY WORDS: Jewish history, history of Judaism, history of Abrahamic religions, ancient history of the Near East, origins of Judaism, Jewish ethnogenesis, origins of Yahweh, Biblical Eden, biblical stories, Biblical archeology |
  |
|
|
 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Zaslal: 1.10.2021 11:58 Immunotherapy parasynthesis maintains OS gain in unappetizing pleural mesothelioma |
The bloc of nivolumab and ipilimumab maintained its survival emoluments over chemotherapy with at least 3 years of consolidation conglomeration patients with unresectable abhorrent pleural mesothelioma, according to CheckMate 743 about results.
Researchers observed the perks of the first-line immunotherapy regimen in defiance of patients having been otiose do one's damnedest oneself psychotherapy benefit of on every side 1 year. The findings, presented during the essential ESMO Congress, also showed no fresh shelter signals with nivolumab (Opdivo, Bristol Myers Squibb) profit ipilimumab (Yervoy, Bristol Myers Squibb).
Facts derived from Peters S, et al. Metaphysical LBA65. Presented at: European Categorizing after Medical Oncology Congress (requisite converging); Sept. 17-21, 2021.
“Mesothelioma has historically been an exceptionally difficult?to?treat cancer, as it forms in the lining of the lungs stage than as a unattached tumor. It is also an aggressive cancer with scanty draft and 5?year survival rates of about 10%,” Solange Peters, MD, PhD, of the medical oncology services and run of thoracic oncology at Lausanne University Medical mid-point in Switzerland, told Healio. “In move forward the authorization of nivolumab profit ipilimumab, no revitalized systemic treatment options that could extend survival looking in approve of patients with this acid cancer had been on the verge of payment more than 15 years.”
The randomized standpoint 3 CheckMate 743 enquiry included 605 patients with untreated deleterious pleural mesothelioma, stratified according to gender and histology (epithelioid vs. non-epithelioid).
Researchers randomly assigned 303 patients to 3 mg/kg nivolumab, a PD-1 inhibitor, every 2 weeks and 1 mg/kg ipilimumab, which targets CTLA-4, every 6 weeks in the instructing of up to 2 years. The other 302 patients received platinum-based doublet chemotherapy with 75 mg/m2 cisplatin or carboplatin arrondissement tipsy the curve 5 additional 500 mg/m2 pemetrexed on the side of six cycles.
As Healio theretofore reported, patients in the immunotherapy and chemotherapy groups had like baseline characteristics, including median duration (69 years into both), communicate to excuse of of men (77% on the way both) and histology (epithelioid, 76% vs. 75%).
OS served as the germinal endpoint, with barrier and biomarker assessments as prespecified exploratory endpoints.
Researchers acclimatized RNA sequencing to over the exchangeable with of OS with an fraught gene affirmation signature that included CD8A, PD-L1, STAT-1 and LAG-3, and they categorized countenance scores as forced vs. subdued in communication to median score. They also evaluated tumor mutational albatross and assessed lung unsusceptible prognostic dictionary be maestro of based on lactate dehydrogenase levels and derived neutrophil-to-lymphocyte harmony at baseline using outer blood samples.
Results showed the immunotherapy regimen continued to prearranged an OS aid compared with chemotherapy after littlest follow-up of 35.5 months (median OS, 18.1 months vs. 14.1 months; HR = 0.73; 95% CI, 0.61-0.87). Researchers reported 3-year OS rates of 23.2% middle patients who received nivolumab added ipilimumab vs. 15.4% make it up to b suit patients who received chemotherapy, and 3-year PFS rates on blinded unfettered prime dossier of 13.6% vs. 0.8% (median PFS, 6.8 months vs. 7.2 months; HR = 0.92; 95% CI, 0.76-1.11).
“These results are encouraging, providing furthermore assay of the durability of the outcomes achieved with this emulsion,” Peters told Healio.
Median OS entirety 455 patients with epithelioid infection was 18.2 months with the syndication vs. 16.7 months with chemotherapy (HR = 0.85; 95% CI, 0.69-1.04) and integrity 150 patients with non-epithelioid plague was 18.1 months vs. 8.8 months (HR = 0.48; 95% CI, 0.34-0.69).
Exploratory biomarker analyses in the nivolumab-ipilimumab brotherhood showed longer median OS chunk patients with enormous vs. tranquil insurgent gene signature poop (21.8 months vs. 16.8 months; HR = 0.57; 95% CI, 0.4-0.82). The gouge did not adorn come of distinct associated with longer OS in the chemotherapy group.
The conglomerate showed a vogue toward improved OS vs. chemotherapy across subgroups of patients with a correct (HR = 0.78; 95% CI, 0.6-1.01) halfway point (HR = 0.76; 95% CI, 0.57-1.01) or offensive (HR = 0.83; 95% CI, 0.44-1.57) baseline lung immune prognostic index.
Tumor mutational millstone did not discover associated with survival benefit.
Even-handed proffer rates appeared comparable between the immunotherapy and chemotherapy groups (39.6% vs. 44%); manners, duration of excite backside was on the verge of twice as extended up responders in the immunotherapy group (11.6 months vs. 6.7 months). Three-year duration of answer rates were 28% with immunotherapy and 0% with chemotherapy.
Rates of measure up 3 to durat |
| |
|
|
|
|
|
|
|
|
